Response Biomedical (RPBIF) 0.8070 $RPBIF Response

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Response Biomedical (RPBIF) 0.8070 $RPBIF

Response Biomedical Corp. Announces Closing of First Tranche of Private Placement
Marketwire Canada - Fri Jun 17, 6:33PM CDT
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jun 17, 2016) - Response Biomedical Corp. ("Response" or the "Company" (TSX:RBM)(OTC:RPBIF) announces the closing of the first tranche of the non-brokered private placement (the "Private Placement" previously announced by the Company on May 30, 2016. In its press release of June 16, 2016, the Company announced that it has entered into subscription agreements for up to 1,785,716 common shares at a price of U.S.$0.56 per share for total gross proceeds of approximately U.S.$1,000,000 in the Private Placement. Under the first tranche of the Private Placement, OrbiMed Advisors LLC ("OrbiMed", an investment management firm focused on the healthcare sector and the Company's largest shareholder, acquired 892,858 common shares for total gross proceeds to the Company of approximately U.S.$500,000. The second tranche of the Private Placement from Shanghai Runda Medical Technology Co., Ltd is expected to close in due course subject to certain regulatory approvals in China being received.
RBM.TO: 1.08 (+0.01)

Response Biomedical Corp. Enters into Definitive Agreements for Going-Private Transaction and Private Placement
Marketwired - Thu Jun 16, 2:32AM CDT
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jun 16, 2016) - Response Biomedical Corp. ("Response" or the "Company" (TSX:RBM)(OTC:RPBIF) announces that it has entered into a definitive arrangement agreement (the "Arrangement Agreement" with 1077801 B.C. Ltd., a company owned by OrbiMed Asia Partners, LP, OrbiMed Private Investments III, LP and OrbiMed Associates III, LP and Shanghai Runda Medical Technology Co., Ltd. ("Runda" pursuant to which 1077801 B.C. Ltd. will acquire all of the issued and outstanding common shares of Response ("Response Shares" for cash consideration of $1.12 per Response Share (except in the case of certain rollover shareholders who will instead receive shares of 1077801 B.C. Ltd. on a 1 for 1 basis) (the "Transaction" by way of a statutory plan of arrangement under the Business Corporations Act (British Columbia) (the "Arrangement". The cash consideration price represents a 51% premium to the closing price of the Response Shares on the Toronto Stock Exchange ("TSX" on June 15, 2016, the date prior to the date of signing of the Arrangement Agreement. OrbiMed Advisors LLC ("OrbiMed", an investment management firm focused on the healthcare sector, and its affiliates currently own 4,970,543 Response Shares, representing 50.1% of the issued and outstanding Response Shares, based on 9,925,256 Response Shares outstanding.
RBM.TO: 1.08 (+0.01)

TSX Delisting Review - Response Biomedical Corp. (Symbol: RBM)
CNW Group - Tue May 31, 7:30AM CDT
DELISTING REVIEW Response Biomedical Corp. (the "Company" - Further to TSX Bulletin 2016-0389 dated April 18, 2016, TSX has decided to extend its review of the eligibility of the common shares (Symbol: RBM) of the Company for continued listing for a period of 30 days.
RBM.TO: 1.08 (+0.01), X.TO: 60.05 (-0.12)

Response Biomedical Corp. Announces Intention to Enter Into Private Placement
Marketwire Canada - Mon May 30, 7:01AM CDT
VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 30, 2016) - Response Biomedical Corp. ("Response" or the "Company" (TSX:RBM)(OTC:RPBIF) announces it intends to enter into a private placement (the "Private Placement" of common shares of the Company for gross proceeds of up to U.S.$1,000,000.
RBM.TO: 1.08 (+0.01)

Response Biomedical Corp. Announces First Quarter 2016 Financial Results
Marketwire Canada - Mon May 16, 4:02PM CDT
VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 16, 2016) - Response Biomedical Corp. ("Response" or the "Company" (TSX:RBM)(OTC:RPBIF), a commercial stage in-vitro medical device company with products for the laboratory and point of care markets, today reported financial results for its first quarter ended March 31, 2016, including a 2016 GAAP net loss of $(1.3 million), or $(0.13) per share, compared with a GAAP net loss of $(1.1 million), or $(0.11) per share in 2015, and 2016 negative Adjusted EBITDA (a non-GAAP financial measure) of $(321,000), compared with a negative Adjusted EBITDA of $(655,000) in 2015.
RBM.TO: 1.08 (+0.01)

Response Biomedical Corp. Awarded Capital Equipment Supplier Contract by Vizient, Inc.
Marketwired - Thu Apr 07, 4:26PM CDT
Response Biomedical Corp. ("Response" or the "Company" (TSX: RBM) (OTC: RPBIF), a commercial stage in-vitro medical device company with products for the laboratory and point of care markets, today reported that it has been awarded a three-year Capital Equipment Supplier Contract with Vizient, Inc. for Response's cardiovascular and infectious disease product lines.
RBM.TO: 1.08 (+0.01)

Response Biomedical Corp. Announces Fourth Quarter and Fiscal 2015 Financial Results
Marketwired - Mon Mar 21, 4:03PM CDT
Response Biomedical Corp. ("Response" or the "Company" (TSX: RBM)(OTC: RPBIF) a commercial stage in-vitro medical device company with products for the laboratory and point of care markets, today reported financial results for its fourth quarter and year ended December 31, 2015, including a 2015 GAAP net loss of $(150,000), or $(0.02) per share, compared with a GAAP net loss of $(2.1 million), or $(0.26) per share in 2014, and 2015 Adjusted EBITDA (a non-GAAP financial measure) of $822,000, compared with a negative Adjusted EBITDA of $(4.0 million) in 2014.
RBM.TO: 1.08 (+0.01)

Response Biomedical Receives Health Canada Approval and CE Mark for the RAMP(R) Procalcitonin Test for Sepsis
Marketwired - Mon Jan 11, 4:00PM CST
Response Biomedical Corp. ("Response" or "the Company" (TSX: RBM)(OTCQB: RPBIF), has received Health Canada approval and CE Mark for a new RAMP(r) diagnostic test that measures the levels of Procalcitonin ("PCT". PCT is a biomarker elevated in the blood of patients suffering from sepsis, also known as blood poisoning. Physicians today use PCT to distinguish bacterial sepsis from other causes of similar symptoms(1,2). The RAMP(r) Procalcitonin test is a rapid diagnostic assay that provides quantitative results in 15 minutes directly from a small blood sample.
RBM.TO: 1.08 (+0.01)

Response Biomedical Receives Health Canada Approval and CE Mark for the RAMP® Procalcitonin Test for Sepsis
Marketwire Canada - Mon Jan 11, 4:00PM CST
Response Biomedical Corp. ("Response" or "the Company" (TSX:RBM)(OTCQB:RPBIF), has received Health Canada approval and CE Mark for a new RAMP(r) diagnostic test that measures the levels of Procalcitonin ("PCT". PCT is a biomarker elevated in the blood of patients suffering from sepsis, also known as blood poisoning. Physicians today use PCT to distinguish bacterial sepsis from other causes of similar symptoms(1,2). The RAMP(r) Procalcitonin test is a rapid diagnostic assay that provides quantitative results in 15 minutes directly from a small blood sample.
RBM.TO: 1.08 (+0.01)

Response Biomedical Corp. Announces Receipt of Fifth Milestone in Co-Development Collaboration
Marketwired - Wed Dec 30, 4:03PM CST
Response Biomedical Corp. ("Response" or "the Company" (TSX: RBM)(OTCQB: RPBIF), has received the fifth milestone of US$720,000 in the Collaboration Agreement with Hangzhou Joinstar Biomedical Technology Co. Ltd. ("Joinstar". The milestone payment was received upon the receipt of certain testing reports for the high throughput rapid immunoassay analyzer developed by Joinstar. On February 16th, 2015 the companies entered into definitive Collaboration and Supply Agreements whereby Response and Joinstar will co-develop components and assays for the new analyzer and Response will provide certain materials to Joinstar required for Joinstar to manufacture and sell these assays specifically to run on their new analyzer.
RBM.TO: 1.08 (+0.01)

Response Biomedical Announces Strategic Alliances in Japan with Alere Medical and Long Time Partner Shionogi
GlobeNewswire - Tue Dec 08, 4:00PM CST
Response Biomedical Corp. ("Response" or "the Company" (TSX:RBM) (OTCQB:RPBIF), a commercial stage in-vitro diagnostics company with products for the laboratory and point of care markets, today reported a restructuring of the marketing of its BNP (B-type natriuretic peptide) products in Japan. Effective January 5, 2016, Alere Medical Co., Ltd. ("Alere Japan" will become the exclusive national distributor in Japan for the marketing and sales of Response manufactured BNP tests and readers. Response's long time partner in Japan, Shionogi & Co. Ltd ("Shionogi", will continue to supply biological reagents to Response under separate license and supply agreements.
RBM.TO: 1.08 (+0.01)

Response Biomedical Corp. Announces Notification of TSX Continued Listing Review
GlobeNewswire - Thu Nov 19, 4:35AM CST
Response Biomedical Corp. ("Response" or "the Company" (TSX:RBM) (OTCQB:RPBIF), a commercial stage in-vitro medical device company with products for the laboratory and point of care markets, today announced that it has received notice that the Toronto Stock Exchange (the "TSX" is reviewing the eligibility for continued listing on the TSX of the common shares of Response pursuant to Part VII of the TSX Company Manual. The TSX initiated its review because the price of Response's shares have traded below $0.68 for 30 consecutive trading days, and as a result, the market value of the publicly-held common shares (as defined by the TSX) did not meet the minimum threshold of $2 million required under the TSX rules. Under the TSX definition, shares held by certain significant shareholders and the Company's directors and officers, which in the case of Response total approximately 70% of its outstanding shares, are excluded from the calculation of publicly-held shares. The Company has been granted 120 days in which to demonstrate compliance with the continued listing requirements of the TSX, pursuant to the TSX's Remedial Review Process. Receipt of this notice has no immediate effect on the listing of the Company's shares.
RBM.TO: 1.08 (+0.01)

Response Biomedical Corp. Announces Third Quarter 2015 Financial Results
GlobeNewswire - Thu Nov 12, 7:43PM CST
Response Biomedical Corp. ("Response" or "the Company" (TSX:RBM) (OTCQB:RPBIF) a commercial stage in-vitro medical device company with products for the laboratory and point of care markets, today reported financial results for its third quarter and nine months ended September 30, 2015. Third quarter highlights include a 60% increase in total revenue, a 10% increase in product sales, a GAAP net income of $729,000, and a positive Adjusted EBITDA of $311,000.
RBM.TO: 1.08 (+0.01)

Response Biomedical Corp. Announces Receipt of Fourth Milestone in Co-Development Collaboration
Marketwired - Tue Sep 08, 7:02AM CDT
Response Biomedical Corp. ("Response" or "the Company" (TSX: RBM)(OTCQB: RPBIF) today announced that it has received the fourth milestone of US$648,000 in the Collaboration Agreement with Hangzhou Joinstar Biomedical Technology Co. Ltd. ("Joinstar". The milestone payment was received upon the delivery of certain materials for the high throughput rapid immunoassay analyzer developed by Joinstar. On February 16th, 2015 the companies entered into definitive Collaboration and Supply Agreements whereby Response and Joinstar will co-develop components and assays for the new analyzer and Response will provide certain materials to Joinstar required for Joinstar to manufacture and sell these assays specifically to run on their new analyzer.
RBM.TO: 1.08 (+0.01)

Response Biomedical Corp. Announces Second Quarter 2015 Financial Results
Marketwire Canada - Fri Aug 14, 4:00PM CDT
Response Biomedical Corp. ("Response" or "the Company" (TSX:RBM)(OTCQB:RPBIF) today reported financial results for its second quarter and six months ended June 30, 2015 including a 39% increase in total revenue, a 16% increase in product sales, positive Adjusted EBITDA of $631,000, and a GAAP net loss of $2,000.
RBM.TO: 1.08 (+0.01)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Bank Hapoalim's Q3 2026: Steady Growth Amid Challenges

Updated Category News Views 0

Digging Deep into Hapoalim's Recent Results Now ain't this a turn of events? Bank Hapoalim rolls out its numbers for Q3 2026, and while there's no confetti dropping from the ceiling, the numbers are telling their own story. Net profit comes to a solid NIS 2,364 million, but we're looking at a landscape that's not all rose-tinted today. The bank's managed to pull off...

Continue Reading
Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China

Updated Category News Views 110

Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...

Continue Reading
HONOR Leads in China, Eyes Middle East Market

Updated Category News Views 23

A Force to be Reckoned With Talk about making waves—HONOR's got the bragging rights now. Sitting pretty at the top among Android smartphone brands in China ain't no small feat. We're looking at a snazzy 12.04% market share for October 2026, all thanks to selling a cool 2.573 million units. The kicker? This ain't even their full potential. They're hustling hard in the...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 258

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Sulzer Rebuilds Petrocedeño Tower: A Milestone in Oil Revival

Updated Category News Views 102

Venezuela's Oil Infrastructure Gets a Crucial Boost No one said reviving a near-busted oil facility in Venezuela would be a walk in the park. But that's just what North American Blue Energy Partners (NABEP) is doing, handing the reins to Sulzer to rebuild a busted crude tower at the Petrocedeño upgrader. This ain't just another run-of-the-mill repair job; this is the...

Continue Reading
Net Zero Efforts to Cost Europe €60B Annually by 2050

Updated Category News Views 38

Hefty Prices Loom Over Net Zero Commitments Well, strap in for a wallet buster, folks. Europe's largest players are staring down the barrel of a colossal €60 billion annual bill to clean up their carbon mess by 2050. That's the ticker in Senken's latest report, 'Pace of Change 2026.' Talks like these remind me there's no such thing as a free lunch, especially when...

Continue Reading
Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 63

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 380

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
NestWorks' C500: Shaking Up CNC at Formnext 2026

Updated Category News Views 41

NestWorks C500: A Game Changer for Makers Folks, gather 'round, because NestWorks is turning heads with their C500 desktop CNC machine. As it lands firmly on TIME’s Best Inventions of 2026 list, this ain't just another gadget adorning a workshop—all eyes are on it at Formnext 2026. From November 17–20, Frankfurt is the stage where NestWorks plans to showcase how...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 106

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading

Top 5 Most Recently Viewed Articles

Investigation Into Guess?, Inc.: Are Fiduciary Duties at Risk?

Updated Category News Views 121

Introduction to the Investigation Recently, a significant issue has arisen concerning Guess?, Inc. (NYSE: GES) and its handling of a pending merger with Authentic Brands Group LLC. This acquisition deal, valued at $16.75 per share, has prompted a legal investigation to determine whether the company's board of directors and top executives may have breached their fiduciary...

Continue Reading
Count Down to Class Action: Important News for GO Investors

Updated Category News Views 281

Important Deadline for Grocery Outlet Holding Corp. Investors As the deadline for the class action lawsuit approaches for Grocery Outlet Holding Corp. (NASDAQ: GO), investors are urged to pay close attention. The law firm Kessler Topaz Meltzer & Check, LLP has announced that investors who purchased or acquired Grocery Outlet securities from November 7, 2023, to May 7,...

Continue Reading
Discover KLIMB Jr.: The Latest in Pet Training Innovation

Updated Category News Views 239

Introducing the KLIMB Jr. by Blue-9 Pet Products Blue-9 Pet Products has made a remarkable stride in pet care with the introduction of the KLIMB Jr., a compact and versatile training platform for dogs and cats. This innovative product serves as a perfect tool for pet owners aiming to enhance their pets’ training and daily enrichment activities. A Tailored Solution for...

Continue Reading
Elsevier, Lancet Awards Highlight Community Health Impact

Updated Category News Views 62

Pioneering Health Awards Make Waves Amidst our swirling universe of breakthroughs and challenges, three research teams just snagged the spotlight. Recognized by the Elsevier Foundation and The Lancet in their first-ever Evidence to Impact Awards. These folks aren't just scribbling in labs—they're rolling up their sleeves and getting those much-needed health solutions...

Continue Reading
k-ID's Kai SDK: Age-Adaptive Design Revolution

Updated Category News Views 139

New Horizons for Developers Today, if you're building an app, you're just as likely to be wrangling with legal regulations as you are writing code. That's where k-ID’s new SDK, Kai, comes into play—it's not just another tool in the shed, it’s the whole toolbox for dealing with age-specific app requirements everywhere. The Changing App Landscape Why does this matter?...

Continue Reading